Table 2.

Characteristics of MSI-high tumors, by BRAF mutation status

	BRAF WT N = 106	BRAF V600E N = 41	OR (95% C.I.)
Age (years)	68.0 (sd = 12.1)	77.7 (sd =9.2)	p <0.0001
Female	53 (65.4)	28 (34.6)	2.15 (1.01 – 4.61)
Male	53 (80.3)	13 (19.7)	1.00
Ashkenazi Jewish	70 (66.7)	35 (33.3)	3.00 (1.15 – 7.79)
Non-Ashkenazi Jewish	36 (85.7)	6 (14.2)	1.00
Never smoked	52 (69.3)	23 (30.7)	0.71 (0.33 – 1.50)
Ever smoked	51 (76.1)	16 (23.9)	1.00
Pack-years	38.8 (sd=26.3)	36.1 (sd=26.1)	p = 0.75
HRT Use	2 (66.6)	1 (33.3)	0.74 (0.06 – 8.63)
No HRT Use	34 (59.7)	23 (40.4)	1.00
Aspirin/NSAID Use	25 (69.4)	11(30.6)	1.24 (0.54 – 2.85)
No Aspirin/NSAID Use	79 (73.8)	28 (26.2)	1.00
1° Fam Hx of CRC	9 (69.2)	4 (30.8)	1.15 (0.33 – 3.97)
No Fam Hx of CRC	96 (72.2)	37 (27.8)	1.00
MSI-high	106 (72.1)	41 (27.9)	-